Clinical Trial Details
| Trial ID: | L5703 |
| Source ID: | NCT03052400 |
| Associated Drug: | Mifepristone 600 Mg Daily |
| Title: | Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus |
| Acronym: | |
| Status: | TERMINATED |
| Study Results: | YES |
| Results: | https://ClinicalTrials.gov/show/NCT03052400/results |
| Conditions: | Type 2 Diabetes Mellitus|Insulin Resistance |
| Interventions: | DRUG: Mifepristone 600 mg daily|DRUG: Placebo |
| Outcome Measures: | Primary: Hemoglobin A1c, Glycemic lowering, Baseline to 3 months | Secondary: Weight, Weight in kg, Baseline to 3 months|Body Mass Index, Body mass index in kg/m\^2, Baseline to 3 months|Systolic BP, Systolic blood pressure, Baseline to 3 months|Diastolic BP, Diastolic blood pressure, Baseline to 3 months|LDL-cholesterol, Low-density lipoprotein cholesterol, Baseline to 3 months|Cortisol, Serum cortisol level (AM), Baseline to 3 months|ACTH, Serum adrenocorticotrophic hormone level (AM), Baseline to 3 months|Uric Acid, Serum uric acid level, Baseline to 3 months|PSA, Prostate-specific antigen level, Baseline to 3 months|Hypoglycemic Events, Symptomatic mild and severe hypoglycemic events, Baseline to 3 months|Adverse Events, Non-hypoglycemia-related adverse events, Baseline to 3 months|Basal Insulin Dose, Total daily basal insulin dosage, Baseline to 3 months |
| Sponsor/Collaborators: | Sponsor: Charles Drew University of Medicine and Science |
| Gender: | MALE |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 8 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT |
| Start Date: | 2017-02-03 |
| Completion Date: | 2021-05-31 |
| Results First Posted: | 2022-10-19 |
| Last Update Posted: | 2023-05-18 |
| Locations: | Charles Drew University of Medicine and Science, Los Angeles, California, 90059, United States |
| URL: | https://clinicaltrials.gov/show/NCT03052400 |
